Market Cap 4.73B
Revenue (ttm) 268.09M
Net Income (ttm) 124.45M
EPS (ttm) N/A
PE Ratio 31.93
Forward PE 43.13
Profit Margin 46.42%
Debt to Equity Ratio 0.00
Volume 126,400
Avg Vol 224,296
Day's Range N/A - N/A
Shares Out 20.04M
Stochastic %K 88%
Beta 1.20
Analysts Strong Sell
Price Target $270.67

Company Profile

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma. The company also pr...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 550 7500
Address:
555 Heritage Drive, Suite 200, Jupiter, United States
JamesTaulman
JamesTaulman May. 29 at 2:01 AM
$LGND – THU: Welcomed Quieter Action as Resistance of the Previous Highs Come Into Play 8:00 PM – Here is our latest chart update for this recent breakout from our Traditional BreakOuts Watch List. https://buyingbreakouts.com/thu-5-28-lgnd-welcomed-quieter-action-as-resistance-of-the-previous-highs-come-into-play/
0 · Reply
JamesTaulman
JamesTaulman May. 28 at 2:20 AM
$LGND – WED: A Bit Volatile After a Nice Run – Some Consolidation Here Would Be Ideal 8:00 PM – Here is our latest chart update for this recent breakout from our Traditional BreakOuts Watch List. https://buyingbreakouts.com/wed-5-27-lgnd-a-bit-volatile-after-a-nice-run-some-consolidation-here-would-be-ideal/
0 · Reply
Estimize
Estimize May. 27 at 1:03 PM
Wall St is expecting 2.01 EPS for $LGND Q2 [Reporting 08/11 BMO] http://www.estimize.com/intro/lgnd?chart=historical&metric_name=eps&utm_co
0 · Reply
JamesTaulman
JamesTaulman May. 27 at 2:25 AM
$LGND – TUE: Shoots Higher +2.6% – Closed Near Session Highs – Volume Only Average 8:15 PM – Here is our latest chart update for this recent breakout from our Traditional BreakOuts Watch List. https://buyingbreakouts.com/tue-5-26-lgnd-shoots-higher-2-6-closed-near-session-highs-volume-only-average/
0 · Reply
JamesTaulman
JamesTaulman May. 23 at 1:59 AM
$LGND – FRI: Posts Bullish Action With Solid Volume-Backed Gains 7:15 PM – Here is our latest chart update for this recent breakout from our Traditional BreakOuts Watch List. We are currently reporting on this stock as an active holding and continue to monitor the stock closely for any technical SELL SIGNALS. The focus always remains on price/volume action around key support levels, including the 10 DMA, 50 DMA, and any nearby trendline or ROUND-$ support. https://buyingbreakouts.com/fri-5-22-lgnd-posts-bullish-action-with-solid-volume-backed-gains/
0 · Reply
JamesTaulman
JamesTaulman May. 22 at 2:30 AM
$LGND – THU: Gains Continue Yet Volume Lighter – Did Clear the Round-$220 9:00 PM – Here is our latest chart update for this recent breakout from our Traditional BreakOuts Watch List. We are currently reporting on this stock as an active holding and continue to monitor the stock closely for any technical SELL SIGNALS. The focus always remains on price/volume action around key support levels, including the 10 DMA, 50 DMA, and any nearby trendline or ROUND-$ support. https://buyingbreakouts.com/thu-5-21-lgnd-gains-continue-yet-volume-lighter-did-clear-the-round-220/
0 · Reply
jewell69
jewell69 May. 21 at 4:47 PM
216.61 x 219.74 fat ugly b a spread $LGND trying 2 replace 20 shares at 216.71 12:44 pm edt 5/21 BAILED OUT and lost money when I s 5/20 220.535 new topic, made money THIS TIME: $NFLX 05/21/2026 Sell Edit cost basis method NFLX NETFLIX INC 26 $89.13 $0.06 $2,317.32 More 05/20/2026 Buy NFLX NETFLIX INC 26 $88.0799 -$2,290.08
1 · Reply
Doozio
Doozio May. 21 at 12:03 AM
If Roger starts rocking in $HRMY ???? $XBI gets $LGND ary ONTO 🐒🍌🧠⏰♾️
0 · Reply
jewell69
jewell69 May. 20 at 7:07 PM
LOST 480.00 ON THIS ONE ! $LGND BUT IT WAS UP 6+% TODAY 5/20 05/20/2026 Sell Edit cost basis method LGND LIGAND PHARMACEUTICALS I 20 $220.535 $0.09 $4,410.61 More 05/13/2026 Sell LGND LIGAND PHARMACEUTICALS I 20 $221.46 $0.09 $4,429.11 More 05/01/2026 Buy LGND LIGAND PHARMACEUTICALS I 40 $232.995 -$9,319.80 More Total $0.18 -$480.08
0 · Reply
BioRich
BioRich May. 20 at 7:02 AM
$TEM $URGN $PLUR $IVA $LGND (Sorry, using this is a placeholder to see how these track over time from today. Posting late so as to not clog the boards or appear as spam)
0 · Reply
Latest News on LGND
Ligand price target raised to $266 from $263 at BofA

2026-05-28T14:28:37.000Z - 1 day ago

Ligand price target raised to $266 from $263 at BofA

TVTX


Ligand to Participate in June Investor Conferences

May 27, 2026, 4:01 PM EDT - 1 day ago

Ligand to Participate in June Investor Conferences


Ligand Pharmaceuticals Proxy statement: Proxy filing

May 18, 2026, 8:00 AM EDT - 11 days ago

Ligand Pharmaceuticals Proxy statement: Proxy filing


Ligand Pharmaceuticals Q1 Earnings Call Highlights

May 8, 2026, 4:13 PM EDT - 20 days ago

Ligand Pharmaceuticals Q1 Earnings Call Highlights


Ligand reports Q1 adjusted EPS $1.63, consensus $1.80

2026-05-07T15:17:53.000Z - 22 days ago

Ligand reports Q1 adjusted EPS $1.63, consensus $1.80


Ligand Pharmaceuticals Earnings Call Transcript: Q1 2026

May 7, 2026, 8:30 AM EDT - 22 days ago

Ligand Pharmaceuticals Earnings Call Transcript: Q1 2026


Ligand Pharmaceuticals Earnings release: Q1 2026

May 7, 2026, 8:30 AM EDT - 22 days ago

Ligand Pharmaceuticals Earnings release: Q1 2026


Ligand Pharmaceuticals Slides: Q1 2026

May 7, 2026, 8:30 AM EDT - 22 days ago

Ligand Pharmaceuticals Slides: Q1 2026


Ligand Pharmaceuticals Quarterly report: Q1 2026

May 7, 2026, 8:30 AM EDT - 22 days ago

Ligand Pharmaceuticals Quarterly report: Q1 2026


Ligand Reports First Quarter 2026 Financial Results

May 7, 2026, 7:00 AM EDT - 22 days ago

Ligand Reports First Quarter 2026 Financial Results


Orchestra BioMed receives $15M payment from Ligand

2026-05-07T05:00:15.000Z - 22 days ago

Orchestra BioMed receives $15M payment from Ligand

OBIO


Ligand to Participate in May Investor Conferences

May 5, 2026, 4:01 PM EDT - 23 days ago

Ligand to Participate in May Investor Conferences


Ligand price target raised to $252 from $235 at RBC Capital

2026-04-28T12:05:59.000Z - 4 weeks ago

Ligand price target raised to $252 from $235 at RBC Capital


Ligand Pharmaceuticals Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 4 weeks ago

Ligand Pharmaceuticals Proxy statement: Proxy filing


Ligand price target raised to $255 from $230 at Stifel

2026-04-27T18:10:15.000Z - 4 weeks ago

Ligand price target raised to $255 from $230 at Stifel

XOMA


Ligand price target raised to $260 from $250 at BofA

2026-04-27T18:00:17.000Z - 4 weeks ago

Ligand price target raised to $260 from $250 at BofA

XOMA


Ligand Pharmaceuticals Transcript: M&A announcement

Apr 27, 2026, 8:00 AM EDT - 4 weeks ago

Ligand Pharmaceuticals Transcript: M&A announcement


Ligand Pharmaceuticals Press release: M&A announcement

Apr 27, 2026, 8:00 AM EDT - 4 weeks ago

Ligand Pharmaceuticals Press release: M&A announcement


Ligand Pharmaceuticals Slides: M&A announcement

Apr 27, 2026, 8:00 AM EDT - 4 weeks ago

Ligand Pharmaceuticals Slides: M&A announcement


Ligand Pharmaceuticals Proxy statement: Proxy filing

Apr 27, 2026, 8:00 AM EDT - 4 weeks ago

Ligand Pharmaceuticals Proxy statement: Proxy filing


Ligand to acquire Xoma for $39.00 per share in cash

2026-04-27T11:26:31.000Z - 4 weeks ago

Ligand to acquire Xoma for $39.00 per share in cash

XOMA


Ligand to buy Xoma for $39 per share, WSJ reports

2026-04-27T10:38:33.000Z - 4 weeks ago

Ligand to buy Xoma for $39 per share, WSJ reports

XOMA


Ligand Pharmaceuticals Is Buying Xoma for Nearly $740 Million

Apr 27, 2026, 6:00 AM EDT - 4 weeks ago

Ligand Pharmaceuticals Is Buying Xoma for Nearly $740 Million


Ligand Pharmaceuticals Proxy statement: Proxy filing

Apr 21, 2026, 8:00 AM EDT - 5 weeks ago

Ligand Pharmaceuticals Proxy statement: Proxy filing


Ligand Pharmaceuticals Proxy statement: Proxy filing

Apr 21, 2026, 8:00 AM EDT - 5 weeks ago

Ligand Pharmaceuticals Proxy statement: Proxy filing


Ligand price target raised to $282 from $276 at Citi

2026-04-15T10:46:47.000Z - 6 weeks ago

Ligand price target raised to $282 from $276 at Citi


Ligand price target raised to $250 from $244 at BofA

2026-04-14T11:19:24.000Z - 6 weeks ago

Ligand price target raised to $250 from $244 at BofA

TVTX


Ligand initiated with a Buy at BofA

2026-03-11T10:11:59.000Z - 2 months ago

Ligand initiated with a Buy at BofA


Ligand to Participate in March Investor Conferences

Mar 4, 2026, 7:00 AM EST - 3 months ago

Ligand to Participate in March Investor Conferences


Ligand files automatic mixed securities shelf

2026-02-27T22:30:35.000Z - 3 months ago

Ligand files automatic mixed securities shelf


Ligand Pharmaceuticals Earnings Call Transcript: Q4 2025

Feb 26, 2026, 8:30 AM EST - 3 months ago

Ligand Pharmaceuticals Earnings Call Transcript: Q4 2025


Ligand Pharmaceuticals Annual report: Q4 2025

Feb 26, 2026, 8:30 AM EST - 3 months ago

Ligand Pharmaceuticals Annual report: Q4 2025


Ligand Pharmaceuticals Earnings release: Q4 2025

Feb 26, 2026, 8:30 AM EST - 3 months ago

Ligand Pharmaceuticals Earnings release: Q4 2025


Ligand Pharmaceuticals Slides: Q4 2025

Feb 26, 2026, 8:30 AM EST - 3 months ago

Ligand Pharmaceuticals Slides: Q4 2025


Ligand Pharmaceuticals Transcript: Investor Day 2025

Dec 9, 2025, 10:30 AM EST - 6 months ago

Ligand Pharmaceuticals Transcript: Investor Day 2025


Ligand Pharmaceuticals Press release: FY 2025

Dec 9, 2025, 10:30 AM EST - 6 months ago

Ligand Pharmaceuticals Press release: FY 2025


Ligand Pharmaceuticals Slides: FY 2025

Dec 9, 2025, 10:30 AM EST - 6 months ago

Ligand Pharmaceuticals Slides: FY 2025


Ligand Hosts 2025 Investor Day and Introduces 2026 Guidance

Dec 9, 2025, 7:00 AM EST - 6 months ago

Ligand Hosts 2025 Investor Day and Introduces 2026 Guidance


Ligand Pharmaceuticals Earnings Call Transcript: Q3 2025

Nov 6, 2025, 8:30 AM EST - 7 months ago

Ligand Pharmaceuticals Earnings Call Transcript: Q3 2025


Ligand Pharmaceuticals Quarterly report: Q3 2025

Nov 6, 2025, 8:30 AM EST - 7 months ago

Ligand Pharmaceuticals Quarterly report: Q3 2025


Ligand Pharmaceuticals Earnings release: Q3 2025

Nov 6, 2025, 8:30 AM EST - 7 months ago

Ligand Pharmaceuticals Earnings release: Q3 2025


Ligand Pharmaceuticals Slides: Q3 2025

Nov 6, 2025, 8:30 AM EST - 7 months ago

Ligand Pharmaceuticals Slides: Q3 2025


Ligand to Participate in November Investor Conferences

Oct 30, 2025, 4:01 PM EDT - 7 months ago

Ligand to Participate in November Investor Conferences


Ligand to Host Investor Day on December 9, 2025

Oct 16, 2025, 7:00 AM EDT - 8 months ago

Ligand to Host Investor Day on December 9, 2025


Ligand to Participate in September Investor Conferences

Aug 19, 2025, 4:00 PM EDT - 10 months ago

Ligand to Participate in September Investor Conferences


Ligand Announces Closing of Convertible Senior Notes Offering

Aug 14, 2025, 4:00 PM EDT - 10 months ago

Ligand Announces Closing of Convertible Senior Notes Offering


Ligand Pharmaceuticals Earnings Call Transcript: Q2 2025

Aug 7, 2025, 8:30 AM EDT - 10 months ago

Ligand Pharmaceuticals Earnings Call Transcript: Q2 2025


Ligand Pharmaceuticals Quarterly report: Q2 2025

Aug 7, 2025, 8:30 AM EDT - 10 months ago

Ligand Pharmaceuticals Quarterly report: Q2 2025


Ligand Pharmaceuticals Earnings release: Q2 2025

Aug 7, 2025, 8:30 AM EDT - 10 months ago

Ligand Pharmaceuticals Earnings release: Q2 2025


Ligand Pharmaceuticals Slides: Q2 2025

Aug 7, 2025, 8:30 AM EDT - 10 months ago

Ligand Pharmaceuticals Slides: Q2 2025


Ligand Partner Pelthos Therapeutics Launches ZELSUVMI™

Jul 10, 2025, 8:00 AM EDT - 11 months ago

Ligand Partner Pelthos Therapeutics Launches ZELSUVMI™


Ligand Announces 2025 Investor Day in New York City

Jun 11, 2025, 7:00 AM EDT - 1 year ago

Ligand Announces 2025 Investor Day in New York City


Ligand to Ring the Nasdaq Opening Bell on May 19, 2025

May 14, 2025, 7:00 AM EDT - 1 year ago

Ligand to Ring the Nasdaq Opening Bell on May 19, 2025


Ligand Pharmaceuticals Earnings Call Transcript: Q1 2025

May 8, 2025, 8:30 AM EDT - 1 year ago

Ligand Pharmaceuticals Earnings Call Transcript: Q1 2025


Ligand Pharmaceuticals Quarterly report: Q1 2025

May 8, 2025, 8:30 AM EDT - 1 year ago

Ligand Pharmaceuticals Quarterly report: Q1 2025


Ligand Pharmaceuticals Earnings release: Q1 2025

May 8, 2025, 8:30 AM EDT - 1 year ago

Ligand Pharmaceuticals Earnings release: Q1 2025


Ligand Pharmaceuticals Slides: Q1 2025

May 8, 2025, 8:30 AM EDT - 1 year ago

Ligand Pharmaceuticals Slides: Q1 2025


Ligand Reports First Quarter 2025 Financial Results

May 8, 2025, 7:00 AM EDT - 1 year ago

Ligand Reports First Quarter 2025 Financial Results


Ligand Pharmaceuticals Proxy statement: Proxy Filing

Apr 22, 2025, 8:00 AM EDT - 1 year ago

Ligand Pharmaceuticals Proxy statement: Proxy Filing


Ligand Pharmaceuticals Proxy statement: Proxy Filing

Apr 22, 2025, 8:00 AM EDT - 1 year ago

Ligand Pharmaceuticals Proxy statement: Proxy Filing


Ligand Pharmaceuticals Earnings Call Transcript: Q4 2024

Feb 27, 2025, 8:30 AM EST - 1 year ago

Ligand Pharmaceuticals Earnings Call Transcript: Q4 2024


Ligand Pharmaceuticals Annual report: Q4 2024

Feb 27, 2025, 8:30 AM EST - 1 year ago

Ligand Pharmaceuticals Annual report: Q4 2024


Ligand Pharmaceuticals Earnings release: Q4 2024

Feb 27, 2025, 8:30 AM EST - 1 year ago

Ligand Pharmaceuticals Earnings release: Q4 2024


Ligand Pharmaceuticals Slides: Q4 2024

Feb 27, 2025, 8:30 AM EST - 1 year ago

Ligand Pharmaceuticals Slides: Q4 2024


Ligand Pharmaceuticals Transcript: Investor Day 2024

Dec 10, 2024, 10:30 AM EST - 1 year ago

Ligand Pharmaceuticals Transcript: Investor Day 2024


Ligand Pharmaceuticals Slides: FY 2024

Dec 10, 2024, 10:30 AM EST - 1 year ago

Ligand Pharmaceuticals Slides: FY 2024


Ligand to Present at Stifel 2024 Healthcare Conference

Nov 14, 2024, 8:00 AM EST - 1 year ago

Ligand to Present at Stifel 2024 Healthcare Conference


Ligand Pharmaceuticals Earnings Call Transcript: Q3 2024

Nov 7, 2024, 8:30 AM EST - 1 year ago

Ligand Pharmaceuticals Earnings Call Transcript: Q3 2024


Ligand Pharmaceuticals Quarterly report: Q3 2024

Nov 7, 2024, 8:30 AM EST - 1 year ago

Ligand Pharmaceuticals Quarterly report: Q3 2024


Ligand Pharmaceuticals Earnings release: Q3 2024

Nov 7, 2024, 8:30 AM EST - 1 year ago

Ligand Pharmaceuticals Earnings release: Q3 2024


Ligand Pharmaceuticals Slides: Q3 2024

Nov 7, 2024, 8:30 AM EST - 1 year ago

Ligand Pharmaceuticals Slides: Q3 2024


Ligand Pharmaceuticals Slides: Corporate Presentation

Sep 10, 2024, 7:00 AM EDT - 1 year ago

Ligand Pharmaceuticals Slides: Corporate Presentation


JamesTaulman
JamesTaulman May. 29 at 2:01 AM
$LGND – THU: Welcomed Quieter Action as Resistance of the Previous Highs Come Into Play 8:00 PM – Here is our latest chart update for this recent breakout from our Traditional BreakOuts Watch List. https://buyingbreakouts.com/thu-5-28-lgnd-welcomed-quieter-action-as-resistance-of-the-previous-highs-come-into-play/
0 · Reply
JamesTaulman
JamesTaulman May. 28 at 2:20 AM
$LGND – WED: A Bit Volatile After a Nice Run – Some Consolidation Here Would Be Ideal 8:00 PM – Here is our latest chart update for this recent breakout from our Traditional BreakOuts Watch List. https://buyingbreakouts.com/wed-5-27-lgnd-a-bit-volatile-after-a-nice-run-some-consolidation-here-would-be-ideal/
0 · Reply
Estimize
Estimize May. 27 at 1:03 PM
Wall St is expecting 2.01 EPS for $LGND Q2 [Reporting 08/11 BMO] http://www.estimize.com/intro/lgnd?chart=historical&metric_name=eps&utm_co
0 · Reply
JamesTaulman
JamesTaulman May. 27 at 2:25 AM
$LGND – TUE: Shoots Higher +2.6% – Closed Near Session Highs – Volume Only Average 8:15 PM – Here is our latest chart update for this recent breakout from our Traditional BreakOuts Watch List. https://buyingbreakouts.com/tue-5-26-lgnd-shoots-higher-2-6-closed-near-session-highs-volume-only-average/
0 · Reply
JamesTaulman
JamesTaulman May. 23 at 1:59 AM
$LGND – FRI: Posts Bullish Action With Solid Volume-Backed Gains 7:15 PM – Here is our latest chart update for this recent breakout from our Traditional BreakOuts Watch List. We are currently reporting on this stock as an active holding and continue to monitor the stock closely for any technical SELL SIGNALS. The focus always remains on price/volume action around key support levels, including the 10 DMA, 50 DMA, and any nearby trendline or ROUND-$ support. https://buyingbreakouts.com/fri-5-22-lgnd-posts-bullish-action-with-solid-volume-backed-gains/
0 · Reply
JamesTaulman
JamesTaulman May. 22 at 2:30 AM
$LGND – THU: Gains Continue Yet Volume Lighter – Did Clear the Round-$220 9:00 PM – Here is our latest chart update for this recent breakout from our Traditional BreakOuts Watch List. We are currently reporting on this stock as an active holding and continue to monitor the stock closely for any technical SELL SIGNALS. The focus always remains on price/volume action around key support levels, including the 10 DMA, 50 DMA, and any nearby trendline or ROUND-$ support. https://buyingbreakouts.com/thu-5-21-lgnd-gains-continue-yet-volume-lighter-did-clear-the-round-220/
0 · Reply
jewell69
jewell69 May. 21 at 4:47 PM
216.61 x 219.74 fat ugly b a spread $LGND trying 2 replace 20 shares at 216.71 12:44 pm edt 5/21 BAILED OUT and lost money when I s 5/20 220.535 new topic, made money THIS TIME: $NFLX 05/21/2026 Sell Edit cost basis method NFLX NETFLIX INC 26 $89.13 $0.06 $2,317.32 More 05/20/2026 Buy NFLX NETFLIX INC 26 $88.0799 -$2,290.08
1 · Reply
Doozio
Doozio May. 21 at 12:03 AM
If Roger starts rocking in $HRMY ???? $XBI gets $LGND ary ONTO 🐒🍌🧠⏰♾️
0 · Reply
jewell69
jewell69 May. 20 at 7:07 PM
LOST 480.00 ON THIS ONE ! $LGND BUT IT WAS UP 6+% TODAY 5/20 05/20/2026 Sell Edit cost basis method LGND LIGAND PHARMACEUTICALS I 20 $220.535 $0.09 $4,410.61 More 05/13/2026 Sell LGND LIGAND PHARMACEUTICALS I 20 $221.46 $0.09 $4,429.11 More 05/01/2026 Buy LGND LIGAND PHARMACEUTICALS I 40 $232.995 -$9,319.80 More Total $0.18 -$480.08
0 · Reply
BioRich
BioRich May. 20 at 7:02 AM
$TEM $URGN $PLUR $IVA $LGND (Sorry, using this is a placeholder to see how these track over time from today. Posting late so as to not clog the boards or appear as spam)
0 · Reply
StockMeister2
StockMeister2 May. 15 at 2:55 PM
$VKTX $LGND is mad at them for not furthering VK2809
0 · Reply
ZacksSCR
ZacksSCR May. 11 at 1:34 PM
$LGND: 1Q:26 Results Highlight Breadth of Portfolio https://buff.ly/SrJXY7P
0 · Reply
MaximoffMACD
MaximoffMACD May. 10 at 7:48 PM
$LGND BIOS always pump this time of year
0 · Reply
Kool_Aid_Mann
Kool_Aid_Mann May. 8 at 7:53 PM
$VRTX $ALNY $REGN Join MNKD as they approach their May 29th pediatric PDUFA!! This is the one that they have been waiting for for 12 years. Lots of delays, but finally here and likely to be the milestone trigger for a big cash deal with big pharma! On top of that, they just got back the green light for Treprostinil DPI in IPF which had them previously trading over $6 until a spat with their partner UTHR. Now, not only is everything copacetic again, but they have also just announced a new molecule colloboration with bigger potential than Trep, Ralinpag DPI! Big royalty model like $LGND But wait, there's more, there is another PDUFA ahead for them for furoscix on July 26th, that will approve a new auto injector that will make this product best in class and reduce COGs by 70% to create massive profits. And lets not forget that nintedabib DPI just finished 1b and is prime for an upfront cash deal! $VCYT Fireworks ahead, fight the Citadel!
0 · Reply
BillionerOfKing
BillionerOfKing May. 7 at 6:18 PM
$LGND Current Stock Price: $211.09 Contracts to trade: $210.0 LGND May 15 2026 Call Entry: $6.00 Exit: $8.20 ROI: 37% Hold ~20 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
StocktwitsEarnings
StocktwitsEarnings May. 7 at 11:10 AM
$LGND Q1 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.67 up 69.68% YoY • Reported revenue of $51.72M up 14.09% YoY • Ligand reaffirms its 2026 full-year financial guidance, expecting adjusted earnings per diluted share of $8.50 to $9.50 and total revenue of $270M to $310M, reflecting partial-year XOMA contribution.
0 · Reply
Doozio
Doozio May. 4 at 2:30 PM
$XBI $AXSM BODI. That wen da huckleberries get $ETON n $DRUG z get $LGND ary ONTO 🐒🍌🧠⏰♾️
1 · Reply
jewell69
jewell69 May. 1 at 4:59 PM
$LGND 1st time by 12:58 pm edt 5/1 05/01/2026 Buy LGND LIGAND PHARMACEUTICALS I 40 $232.995 -$9,319.80
0 · Reply
jewell69
jewell69 May. 1 at 4:50 PM
trying 2 by 40 $LGND 231.80 now b a 231.67 x 234.32 hi 236.22 lo 226.47 SO FAR as of 12:48 pm edt on 5/1 they also raised numbers Rating — Buy Target Price $230.00 $255.00 FY26E EPS (adj.) $8.66 $9.19 FY27E EPS (adj.) $9.53 $11.44 FY26E Rev (net) $264.3 $289.6 FY27E Rev (net) $308.2 $381.9 the numbers on the left are before, the numbers on the right are now. they are paying just + 14% over average price of the new company.
0 · Reply
jewell69
jewell69 May. 1 at 4:44 PM
$LGND more stifel 4/27 narrative: ... adding highly complementary, synergistic, and diversified assets to its portfolio and pipeline (expected closing 3Q26). XOMA has a portfolio of long-dated royalty revenues—seven commercial (three growth drivers in Vabysmo, Ojemda and Miplyffa), 14 late-stage, and >100 early-stage assets—strengthening LGND’s leadership position in development stage royalty aggregation and offering a layered strategy to LGND’s growth profile. The XOMA acquisition effectively doubles the size of LGND’s royalty portfolio and brings immediate accretion, increasing 2026 guidance by $25MN ($270–310mn) in royalty revenues and Adjusted Core EPS by $0.50/share ($8.50 9.50). Importantly, despite using cash and its credit line (resulting in minimal dilution), LGND is maintaining its capital flexibility, with cash flow increasing to $300MN, fully funding its annual capital deployment goal of $150 - $250 mn per year.
0 · Reply
jewell69
jewell69 May. 1 at 4:43 PM
5/1/26 not sure what STIFEL's problem is w/ their focus list, but 3/18 they had both $LGND and $JAZZ with a pt of 230 for both of them. at the time of their writing, jazz was at 181.37 but 5/1/26 it is at 202.30 and LGND was at 211 on 3/18, and as of 5/1 it is at 233.48 (so it is above its pt! but they wrote about it on 4/27 and raised pt from 230 to 255 XOMA Solidifies a Unique Position in Biotech Royalty Aggregation and Development-Stage Assets; Raise TP to $255 $XOMA 40.92 on 5/1 but buyout price is ONLY 39.00
0 · Reply
biolover
biolover Apr. 30 at 11:53 PM
$LGND $VKTX This is meritless termination of agreement that will go nowhere Could be driven by a third party that is trying to license Vk2809 from $VKTX for cheap ( as recently rumored ) Now the whole BTR agonism is a weak class and doesn’t have long term competitive edge, regardless whether BB are invested in it or not VK CEO was planning to raise in Nov 2024 but dropped data at OW 2 days prior to election in the most bear market. He can’t veer resources from BIC VK2735 competing in future with $LLY king TZP. This is no impact story long term.. it could force a licensing deal with BP and infuse cash to VK
1 · Reply